NASDAQABSI

sutthirat sutthisumdang Morgan Stanley initiated coverage of Absci (NASDAQ:ABSI) with an overweight rating, noting it sees the stock as “an economical way of gaining exposure to the theme of AI in biotech/drug development.” The investment bank said it sees the stock’s risk-reward skewing to the upside ahead of catalysts andContinue Reading